About Xeris Pharmaceuticals
Xeris Pharmaceuticals is a company based in Chicago (United States) founded in 2005 by Steve Prestrelski.. Xeris Pharmaceuticals has raised $110.43 million across 21 funding rounds from investors including Hayfin, HHS and Epilepsy Foundation. The company has 394 employees as of December 31, 2024. Xeris Pharmaceuticals has completed 1 acquisition, including Strongbridge Biopharma. Xeris Pharmaceuticals operates in a competitive market with competitors including Insulet, Companion Medical, Qlibrium, Windgap Medical and SHL Group, among others.
- Headquarter Chicago, United States
- Employees 394 as on 31 Dec, 2024
- Founders Steve Prestrelski
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Xeris Biopharma Holdings, Inc.
-
Annual Revenue
$203.07 M23.89as on Dec 31, 2024
-
Net Profit
$-54.84 M11.92as on Dec 31, 2024
-
EBITDA
$-21.02 M31.86as on Dec 31, 2024
-
Total Equity Funding
$110.43 M (USD)
in 21 rounds
-
Latest Funding Round
-
Investors
Hayfin
& 15 more
-
Employee Count
394
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Xeris Pharmaceuticals
Xeris Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol XERS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Leadership Team
30 people
Software Development Team
12 people
Product Management Team
11 people
Operations Team
8 people
Finance and Accounting
7 people
Sales and Marketing
6 people
Legal and Compliance
5 people
Senior Team
4 people
Unlock access to complete
Funding Insights of Xeris Pharmaceuticals
Xeris Pharmaceuticals has successfully raised a total of $110.43M across 21 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 21
- Last Round Last Round
-
First Round
First Round
(01 Dec 2005)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2022 | Amount | Post-IPO - Xeris Pharmaceuticals | Valuation |
investors |
|
| Mar, 2021 | Amount | Post-IPO - Xeris Pharmaceuticals | Valuation |
investors |
|
| Mar, 2018 | Amount | Series C - Xeris Pharmaceuticals | Valuation | Merieux Equity Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Xeris Pharmaceuticals
Xeris Pharmaceuticals has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Hayfin, HHS and Epilepsy Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private debt investments are directed across multiple sectors.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Early-stage tech and life sciences focused family office firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Xeris Pharmaceuticals
Xeris Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Strongbridge Biopharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drugs for rare endocrine disorders are developed and advanced.
|
1996 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Xeris Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xeris Pharmaceuticals Comparisons
Competitors of Xeris Pharmaceuticals
Xeris Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Companion Medical, Qlibrium, Windgap Medical and SHL Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| domain | founded_year | HQ Location |
Smart insulin pens with Bluetooth smartphone connectivity are developed.
|
|
| domain | founded_year | HQ Location |
On-body drug delivery systems are developed using advanced microfluidic technology.
|
|
| domain | founded_year | HQ Location |
Drug delivery autoinjectors for anaphylaxis treatment are provided.
|
|
| domain | founded_year | HQ Location |
Drug delivery devices are manufactured by SHL Group in Switzerland.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xeris Pharmaceuticals
Frequently Asked Questions about Xeris Pharmaceuticals
When was Xeris Pharmaceuticals founded?
Xeris Pharmaceuticals was founded in 2005.
Where is Xeris Pharmaceuticals located?
Xeris Pharmaceuticals is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Who is the current CEO of Xeris Pharmaceuticals?
Paul Edick is the current CEO of Xeris Pharmaceuticals.
Is Xeris Pharmaceuticals a funded company?
Xeris Pharmaceuticals is a funded company, having raised a total of $110.43M across 21 funding rounds to date. The company's 1st funding round was a Series C of $10M, raised on Dec 01, 2005.
How many employees does Xeris Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Xeris Pharmaceuticals is 394.
What is the annual revenue of Xeris Pharmaceuticals?
Annual revenue of Xeris Pharmaceuticals is $203.07M as on Dec 31, 2024.
What does Xeris Pharmaceuticals do?
Xeris Pharmaceuticals was founded in 2005 in Chicago, United States, within the biotechnology sector. Liquid-stable injectables are developed for subcutaneous and intramuscular drug delivery. A ready-to-inject glucagon formulation, Gvoke, is indicated for severe hypoglycemia treatment in adult and pediatric diabetic patients. Proprietary XeriSol and XeriJect technologies are applied to create non-aqueous formulations of peptides, proteins, and antibodies.
Who are the top competitors of Xeris Pharmaceuticals?
Xeris Pharmaceuticals's top competitors include Insulet, Companion Medical and Windgap Medical.
Is Xeris Pharmaceuticals publicly traded?
Yes, Xeris Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol XERS.
How many acquisitions has Xeris Pharmaceuticals made?
Xeris Pharmaceuticals has made 1 acquisition, including Strongbridge Biopharma.
Who are Xeris Pharmaceuticals's investors?
Xeris Pharmaceuticals has 16 investors. Key investors include Hayfin, HHS, Epilepsy Foundation, Armistice Capital, and Deerfield.
What is Xeris Pharmaceuticals's ticker symbol?
The ticker symbol of Xeris Pharmaceuticals is XERS on NASDAQ.